Form 4: Maria Palasis Acquires 11,247 Shares of Beta Bionics Stock
SEC Form 4 Filing
Director Maria Palasis acquired 11,247 shares of Beta Bionics, Inc. common stock on March 15, 2025, through a restricted stock unit award.
Summary
- On March 15, 2025, Maria Palasis, a director of Beta Bionics, Inc., acquired 11,247 shares of common stock.
- The acquisition was a result of a restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.
- The price per share was $0.
- Following the transaction, Maria Palasis beneficially owns 11,247 shares of Beta Bionics common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's stock acquisition, which can be interpreted as a slightly positive sign of confidence, but it's not inherently a strong indicator of future performance.
Positives
- A director's acquisition of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for insiders of publicly traded companies. It provides transparency into the transactions of company directors and officers.
Key Dates
| Date | Description |
|---|---|
| 03/15/2025 | Date of transaction: Maria Palasis acquired 11,247 shares of Beta Bionics common stock. |
| 03/18/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.